US20100297599A1 - Transparent cooling gel - Google Patents

Transparent cooling gel Download PDF

Info

Publication number
US20100297599A1
US20100297599A1 US12/733,970 US73397008A US2010297599A1 US 20100297599 A1 US20100297599 A1 US 20100297599A1 US 73397008 A US73397008 A US 73397008A US 2010297599 A1 US2010297599 A1 US 2010297599A1
Authority
US
United States
Prior art keywords
gelatin
cooling
solution
gel
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/733,970
Other languages
English (en)
Inventor
Bernd W. Mueller
Klaus Sommermeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi Deutschland GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to FRESENIUS KABI DEUTSCHLAND GMBH reassignment FRESENIUS KABI DEUTSCHLAND GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MUELLER, BERND-W., SOMMERMEYER, KLAUS
Publication of US20100297599A1 publication Critical patent/US20100297599A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts

Definitions

  • This invention relates to the technical field of cooling organs in transplantation medicine, in particular to a cooling gel.
  • cooling the tissue or organ to be transplanted is a common measure to reduce the speed of metabolic processes and achieve a preservation of the organs. Temperatures as low as ⁇ 5° C. are achieved by means of finely crushed ice preparations. Since it is necessary to work in a sterile environment, this finely crushed ice usually is produced by freezing sterile isotonic saline or 5% glucose solution, which are commercially available as infusion solutions filled in bags.
  • Freezing is effected in the packaging material at temperatures ⁇ 15° C. in a deep freezer. Subsequently, the ice block obtained is converted into a finely crushed ice slush by applying mechanical energy onto the bag, such as a hammer blow. Subsequently, the comminuted ice is removed in a sterile environment and the organ or tissue is treated with the same.
  • the crushed ice is subject to further requirements. First of all, it should be comminuted so fine that it can be formed around the organ region and can also be placed around smaller areas. Furthermore, the aqueous solution obtained when melting the ice slush should rather have a pH in the range between 5 and 7 and should be approximately isotonic, i.e. should rather have physiological conditions, so as not to damage the tissue. All substances obtained must be medically compatible, so that the rest of the thawed solution possibly left in the operating area does not present a risk. The latter is achieved by freezing isotonic, pH-neutral 0.9% saline or e.g. also a 5% glucose solution, which are employed as infusion solutions. After melting such solutions, the same are physiologically well-tolerated and do not damage the organs.
  • the ice mixtures described above have the disadvantage that they are not optimal in mechanical terms for enclosing e.g. small organ areas, i.e. they have no flexibility.
  • EP 1 649 842 describes the use of a cooling gel for cooling organs as a cooling material in an envelope suitable for this purpose.
  • the direct contact of the cooling gel with the organ is not described.
  • a composition which is particularly suitable for such purpose is not disclosed.
  • EP 970 707 describes a gelatin-based cooling gel.
  • the cooling gel described there neither is used for cooling organs nor is the composition adapted for such application.
  • a cooling gel of the invention is soft and formable at temperatures between ⁇ 5° C. and +4° C. and while being physiologically acceptable, also has the necessary cold capacity for cooling organ and tissue regions.
  • cooling gel is liquefied at temperatures >5° C. and easily runs off from the organs after thawing and thus is easily removable.
  • the preparation exclusively contains non-toxic constituents, so that, in case residual amounts are left in the organism after performing the cooling, the same is completely harmless.
  • Such cooling gel has a gelatin content of 3-20 wt-%, preferably between 6 and 10 wt-%.
  • Such composition advantageously contains electrolytes which are physiologically acceptable, such as sodium, potassium, magnesium, calcium and lactate, at least are isotonized, but possibly can also be enriched up to an osmolarity of 600 mosmol/kg.
  • the gelling range of such gels ideally lies between +5° C. and ⁇ 5° C.
  • Succinyl gelatin is a gelatin cross-linked by succinic acid.
  • cooling gels in which succinyl gelatin is used as gelatin therefore have an ideal mix of mechanical stability and good formability within the highly relevant temperature range of ⁇ 5° C. to +4° C. and in addition have a good cooling capacity.
  • a cooling preparation of the invention can be produced from an aqueous solution, be filled in plastic containers and sterilized, similar to the case of known gelatin preparations which are used as plasma volume substitute.
  • the cooling preparation only consists of gelatin or gelatin derivatives, lactate and electrolytes. Electrolytes preferably are contained in the following concentrations: 150-300 mmol/l sodium, 5-10 mmol/l potassium, 1.5-3 mmol/l magnesium, 1.5-3 mmol/l calcium, 100-200 mmol/l chloride. Lactate preferably is contained in the concentration of 30-60 mmol/l.
  • compositions of the invention differ from the latter preparations by the much higher content of gelatin derivative and possibly also by the higher content of electrolytes.
  • the aqueous solution thus obtained is filled in a container, such as a polyethylene or PVC bag, and is converted into the transparent gel form at temperatures of ⁇ 8° C. to 3° C. (e.g. by putting it into a freezer adjusted to the corresponding temperature).
  • gelling is performed at temperatures of ⁇ 5° C. to 1° C.
  • the preparation can be deep-frozen at ⁇ 10° C. to ⁇ 30° C., preferably ⁇ 15° C. to ⁇ 20° C., particularly preferably at approximately ⁇ 18° C., and the deep-frozen hard preparation can then be heated to a temperature of ⁇ 5° C. or more and thus be transferred into a gel-like consistency.
  • a mechanically easily formable structure thus is assumed within about 60 minutes, which is transparent.
  • This mass can be stored in a refrigerator at temperatures of ⁇ 5° C. to 4° C. for up to 24 hours, and in this period it can be used as a cooling preparation.
  • a deep-frozen preparation can also be put into a refrigerator of 2-8° C. Within about 12 hours, the same assumes a formable, transparent gel-ice structure which can likewise be used as a cooling preparation within the following 24 hours.
  • Gelatin is a collagenic protein.
  • collagen occurring in the animal body is not water-soluble. It consists of triple helices of the collagenic proteins, which congregate to collagen fibrils and thus form bones, cartilages, vessels etc.
  • Gelatin usually is obtained from animal collagen, frequently from pork rinds, but every gelatin from natural collagen is suitable for the invention.
  • collagen first is digested and the triple helices are broken up. The collagenic protein thus is transferred into a water-soluble form. With correspondingly high gelatin concentrations in the solution, the collagenic proteins are cross-linked at lower temperatures and form a gel-like consistency.
  • the properties of the natural gelatin can be changed by adding an agent to the gelatin which changes the cross-linking properties of the gelatin.
  • cross-linking agents such as urea or succinic acid (succinyl acid) or its salt, gelatin derivatives are obtained.
  • gelatin or gelatin derivatives in medical solutions is known from commonly used plasma or blood volume expanders. These solutions can contain gelatin derivatives such as succinyl gelatin, oxypolygelatin or urea cross-linked gelatin solutions, but differ from the preparations of the invention by the much smaller concentration range of the gelatin derivative.
  • the invention is practicable for the skilled person by varying said parameters for each physiologically acceptable cross-linked gelatin.
  • succinyl gelatin compared to natural gelatin, urea cross-linked gelatin or oxypolygelatin, is particularly useful to form mechanically sufficient gels at deep temperatures.
  • succinyl gelatin describes a gelatin derivative cross-linked with succinic acid or its salt or succinic anhydride, and the term gelatin succinate also is used as a synonym.
  • the preparations of the invention ideally should be sufficiently liquid at room temperature, so that they can easily be removed again from the cooled organ area.
  • the liquid phase offers the advantage at room temperature that such solutions can be filled or produced more easily.
  • gelatin concentrations below 3% like those of commercially available gelatin infusion solutions used as plasma volume expanders, do not lead to gels with the desired mechanical stability and, depending on their chemical structure, in part form gels only with difficulty. Such preparations pass over too fast, i.e. within an only small temperature range, from a highly formable but mechanically not sufficiently stable condition into a mechanically highly stable non-formable condition.
  • the osmolality can be adjusted up to 650 mosmol/kg, since such a range still is acceptable for infusions which are injected into a peripheral vein.
  • An osmolality in the range from 280-600 is preferred, and a range from 400-550 mosmol/kg is particularly preferred.
  • the crystallization temperature of the ice can be adjusted correspondingly.
  • Gelatin preparations with gelatin succinate with a concentration >3% are quite particularly preferred. This gelatin derivative forms mechanically sufficiently stable gels already at relatively low concentrations as compared to oxypolygelatin derivatives and urea cross-linked gelatin preparations.
  • the strength of the gelatin preparations can be increased up to a content of 3 mmol/l by a physiological addition of magnesium or calcium.
  • the preferred solutions can be prepared from photogelatin, although all natural gelatins and their derivatives can be used. Gelatins or gelatin derivatives with a mean molecular weight of 25-45 kD are preferred. The same are dissolved in water for injections and possibly decomposed thermally, thereafter cross-linked or derivatized with succinic anhydride.
  • the solutions can be depyrogenized by means of hydrogen peroxide.
  • the solution After addition of the electrolytes for obtaining isotonic conditions or of calcium or magnesium, the solution ideally is sterile-filtered, filled in plastic containers and/or heat-sterilized.
  • T 0 ⁇ 5° C. ⁇ 5° C.
  • T 1 h ⁇ 2.5° C. ⁇ 3.5° C.
  • T 2 h ⁇ 2° C. ⁇ 3.5° C.
  • T 3 h ⁇ 1° C. ⁇ 3.5° C.
  • T 4 h 0° C. 0° C.
  • Both gels are mechanically stable with hardly a tendency towards flowing.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
US12/733,970 2007-10-01 2008-09-17 Transparent cooling gel Abandoned US20100297599A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007047040A DE102007047040A1 (de) 2007-10-01 2007-10-01 Transparentes Kältegel
DE102007047040.3 2007-10-01
PCT/EP2008/007789 WO2009046820A2 (de) 2007-10-01 2008-09-17 Transparentes kältegel

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/007789 A-371-Of-International WO2009046820A2 (de) 2007-10-01 2008-09-17 Transparentes kältegel

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/098,903 Division US8865397B2 (en) 2007-10-01 2013-12-06 Method for cooling an organ with a transparent cooling gel

Publications (1)

Publication Number Publication Date
US20100297599A1 true US20100297599A1 (en) 2010-11-25

Family

ID=40435239

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/733,970 Abandoned US20100297599A1 (en) 2007-10-01 2008-09-17 Transparent cooling gel
US14/098,903 Expired - Fee Related US8865397B2 (en) 2007-10-01 2013-12-06 Method for cooling an organ with a transparent cooling gel

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/098,903 Expired - Fee Related US8865397B2 (en) 2007-10-01 2013-12-06 Method for cooling an organ with a transparent cooling gel

Country Status (6)

Country Link
US (2) US20100297599A1 (de)
EP (2) EP3123861A1 (de)
JP (1) JP2010540478A (de)
CN (1) CN101808510A (de)
DE (1) DE102007047040A1 (de)
WO (1) WO2009046820A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11485953B2 (en) 2016-10-04 2022-11-01 Transwell Biotech Co., Ltd. Compositions and methods for maintaining cell viability
CN108338160B (zh) * 2018-04-27 2021-08-27 张长水 一种毛囊保存液及其制备方法
CN108849855B (zh) * 2018-07-19 2021-05-11 成都清科生物科技有限公司 一种脂肪组织离体保存液及其制备方法
KR102182077B1 (ko) * 2020-04-29 2020-11-23 (주)바이오다인 세포 고정용 알코올계 젤리 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827419A (en) * 1954-09-24 1958-03-18 Charles B Knox Gelatine Co Inc Acylated gelatins and their preparations
US4604379A (en) * 1984-06-18 1986-08-05 Curators Of The University Of Missouri Dialysis solutions containing cross-linked gelatin
US20010049140A1 (en) * 2000-01-14 2001-12-06 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US20040053205A1 (en) * 2000-11-22 2004-03-18 David Potts Flush preservation solution
US20050119170A1 (en) * 2001-03-06 2005-06-02 Bouwstra Jan B. Recombinant gelatin-like proteins for use as plasma expanders
US20050288235A1 (en) * 1998-05-15 2005-12-29 Chaoying Zhao Novel pharmaceutical compositions for treating and saving and the method for the preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA702706B (en) * 1969-04-28 1971-12-29 Knox Gelatine Inc Blood plasma substitute
DE2532183C3 (de) * 1975-07-18 1982-03-04 Behringwerke Ag, 3550 Marburg Polyionische isotonische Salzlösung zur Konservierung von Erythrozyten oder zur Perfusion und zur Konservierung von zur Transplantion bestimmter Organen
JPS5925873A (ja) * 1982-08-04 1984-02-09 Nippon Oil Co Ltd 保冷用ゲルの製造法
JPS6127901A (ja) * 1984-07-16 1986-02-07 Kanegafuchi Chem Ind Co Ltd 生体を保存する方法
DE3500268A1 (de) 1985-01-05 1986-07-10 Hoechst Ag, 6230 Frankfurt Praeparate mit verzoegerter wirkung, verfahren zu deren herstellung sowie entsprechende mittel zur human- bzw. veterinaermedizinischen anwendung
US6352707B1 (en) * 1992-02-24 2002-03-05 Anton-Lewis Usala Transplant encapsulation in a hydrogel matrix to obscure immune recognition
JPH089966A (ja) * 1994-06-30 1996-01-16 Sumitomo Bakelite Co Ltd 動物細胞の輸送方法
JPH089961A (ja) * 1994-06-30 1996-01-16 Sumitomo Bakelite Co Ltd 培養器およびその製造方法
SE505499C2 (sv) * 1995-12-15 1997-09-08 Stiftelsen Facthor Förvaringslösning för organ och vävnad eller delar därav från människor och djur innehållande kalcium och nitroglycerin, användning därav samt förfarande för förvaring därmed
DE19735460A1 (de) * 1997-08-16 1999-02-18 Rolf Prof Dr Med Zander Spül- oder Lagerungsflüssigkeit für Blutzellen
JP3706751B2 (ja) * 1998-10-07 2005-10-19 ダイヤ製薬株式会社 保冷・保湿用ゲル及び保冷・保湿用ゲル積層体
US6335088B1 (en) 1998-07-06 2002-01-01 Daiya Pharmaceutical Co., Ltd. Moisture-retentive cooling gel, moisture-retentive cooling gel laminate, and moisture-retentive cooling plaster
US6413713B1 (en) * 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
DE19907257A1 (de) * 1999-02-21 2000-09-14 Bernd Horst Meier Mittel zur Steuerung der Diffusion von Injektionslösungen
JP2002538185A (ja) * 1999-03-11 2002-11-12 ハイパーベイリック システムズ 血小板を保存するための組成物及び方法
CN1293958A (zh) * 1999-10-29 2001-05-09 陈蓁 保存生物材料的方法和设备
GB0031065D0 (en) * 2000-12-20 2001-01-31 Univ Cardiff Preservation of cells
US20060122669A1 (en) 2004-10-25 2006-06-08 Kansoul Hassan A Method and apparatus for insulating body organs during transplantation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827419A (en) * 1954-09-24 1958-03-18 Charles B Knox Gelatine Co Inc Acylated gelatins and their preparations
US4604379A (en) * 1984-06-18 1986-08-05 Curators Of The University Of Missouri Dialysis solutions containing cross-linked gelatin
US20050288235A1 (en) * 1998-05-15 2005-12-29 Chaoying Zhao Novel pharmaceutical compositions for treating and saving and the method for the preparation thereof
US20010049140A1 (en) * 2000-01-14 2001-12-06 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US20040053205A1 (en) * 2000-11-22 2004-03-18 David Potts Flush preservation solution
US20050119170A1 (en) * 2001-03-06 2005-06-02 Bouwstra Jan B. Recombinant gelatin-like proteins for use as plasma expanders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Haemaccel Product Information Sheet, AFT Pharmaceuticals Ltd. 2005. *
Product literature for Gelifundol®, Biotest Pharmaceuticals, 1993. *
Product literature for Gelofusine®, B. Braun, 2002. *
Product literature for Hextend®, BioTime, Inc., 1999. *
Vars et al., VARIOUS PLASMA EXPANDERS IN ANIMALS, 1952, Annals of the New York Academy of Sciences, 55: 496-503. *

Also Published As

Publication number Publication date
JP2010540478A (ja) 2010-12-24
EP3123861A1 (de) 2017-02-01
US8865397B2 (en) 2014-10-21
EP2205066A2 (de) 2010-07-14
US20140093863A1 (en) 2014-04-03
DE102007047040A1 (de) 2009-04-16
WO2009046820A3 (de) 2009-12-30
EP2205066B1 (de) 2016-04-06
CN101808510A (zh) 2010-08-18
WO2009046820A2 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
US5571801A (en) Plasma expander and blood substitute
US8865397B2 (en) Method for cooling an organ with a transparent cooling gel
JP5180912B2 (ja) 灌流の応用における使用のための方法および組成物
US5574019A (en) Method of perfusing a primate
JPH01246201A (ja) 臓器保存用溶液
JP2009247276A (ja) 生体供給用、生体移植用、生体添加用、生体投与用の解凍器官若しくは組織または解凍細胞群とその製造方法及びそれらに用いる過冷却液並びに製造装置
AU6427699A (en) Compositions and methods for preserving platelets
JPH02115128A (ja) 組織洗浄溶液
JPH03188001A (ja) 臓器保存用溶液
SU609524A1 (ru) Раствор дл замораживани костного мозга
RU1772911C (ru) Раствор для консервирования костного мозга млекопитающих при низкой температуре
JPH0617312B2 (ja) 血管閉塞剤
KR880001807B1 (ko) 포유류 생세포를 함유하는 생물 조직을 보존하기 위한 보존용 제품
JPH1025201A (ja) 歯牙保存液
Karimi et al. Comparison of bend angle measurements in fresh cryopreserved cartilage specimens after electromechanical reshaping
CN1040815A (zh) H速冻液及玻璃化储存皮肤的方法
Fahy et al. Application of Farrant's principle to preservation of mammalian kidney cortical slices
CN109010804A (zh) 用于控制外科手术出血的白蛋白纳米球制剂
Fishbein et al. External-internal ice and functional-structural damage in mouse liver mitochondria as a function, of cooling rate
SK6282000A3 (en) Physiologically acceptable aqueous solutions and methods for their use
Voss et al. A thermodynamic procedure for the long-term preservation of organs and parts of organs in animal experiments
JPH0688881B2 (ja) 移植器官の保存方法
CN1069067A (zh) 生物组织细胞包埋剂的生产工艺
JPS6353961B2 (de)

Legal Events

Date Code Title Description
AS Assignment

Owner name: FRESENIUS KABI DEUTSCHLAND GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUELLER, BERND-W.;SOMMERMEYER, KLAUS;REEL/FRAME:024784/0498

Effective date: 20100331

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION